Other
Payments for Repurchase of Common Stock
Vertex Pharmaceuticals Payments for Repurchase of Common Stock increased by 162.4% to $336.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 20.9%, from $426.10M to $336.90M. Over 4 years (FY 2021 to FY 2025), Payments for Repurchase of Common Stock shows an upward trend with a 9.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalLower is better
VolatilityModerate
First reportedQ1 2016
Last reportedQ1 2026May 5, 2026
How to read this metric
Higher spending indicates a commitment to returning capital to shareholders or offsetting dilution from stock-based compensation.
Detailed definition
The cash outflow associated with the company's repurchase of its own common shares from the open market. This is a prima...
Peer comparison
Standard capital return metric for mature public companies.
Metric ID:
other_payments_for_repurchase_of_common_stockHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $632.30M | $368.20M | $0.00 | $0.00 | $0.00 | $0.00 | $106.90M | $106.90M | $106.90M | $106.90M | $131.20M | $320.30M | $307.70M | $417.90M | $426.10M | $391.80M | $1.07B | $128.40M | $336.90M |
| QoQ Change | — | — | -41.8% | -100.0% | — | — | — | — | +0.0% | +0.0% | +0.0% | +22.7% | +144.1% | -3.9% | +35.8% | +2.0% | -8.0% | +173.4% | -88.0% | +162.4% |
| YoY Change | — | — | — | — | — | -100.0% | -100.0% | — | — | — | — | +22.7% | +199.6% | +187.8% | +290.9% | +224.8% | +22.3% | +248.1% | -69.3% | -20.9% |
Range$0.00 – $1.07B
Avg YoY Growth+82.4%
Median YoY Growth+22.7%
Payments for Repurchase of Common Stock at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's payments for repurchase of common stock?
- Vertex Pharmaceuticals (VRTX) reported payments for repurchase of common stock of $336.90M in Q1 2026.
- How has Vertex Pharmaceuticals's payments for repurchase of common stock changed year-over-year?
- Vertex Pharmaceuticals's payments for repurchase of common stock decreased by 20.9% year-over-year, from $426.10M to $336.90M.
- What is the long-term trend for Vertex Pharmaceuticals's payments for repurchase of common stock?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's payments for repurchase of common stock has grown at a 9.1% compound annual growth rate (CAGR), from $1.43B to $2.02B.
- What does payments for repurchase of common stock mean?
- Cash spent by the company to buy back its own common stock.